-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-517991-39-00
5
2025-07-22
Asthma
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-515280-60-00
5
2025-05-29
Lupus nephritis
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-509070-36-00
5
2025-03-18
Major Depressive Disorder with Insomnia Symptoms
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-500583-36-00
5
2024-07-01
Acute Schizophrenia
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2025-523974-18-00
5
2026-04-30
Obesity
-
2023-509600-15-00
5
2024-10-18
Type 2 Diabetes
-
2023-507261-25-00
5
2024-10-03
Nonmuscle Invasive Bladder Cancer